Home/Filings/4/0001780088-25-000005
4//SEC Filing

Ticho Barry 4

Accession 0001780088-25-000005

CIK 0001623526other

Filed

Dec 2, 7:00 PM ET

Accepted

Dec 3, 8:23 PM ET

Size

14.7 KB

Accession

0001780088-25-000005

Insider Transaction Report

Form 4
Period: 2025-12-01
Ticho Barry
CHIEF MEDICAL OFFICER
Transactions
  • Exercise/Conversion

    Common Stock

    2025-12-01+11,98119,176 total
  • Sale

    Common Stock

    2025-12-02$29.56/sh1,244$36,77517,932 total
  • Sale

    Common Stock

    2025-12-02$30.14/sh762$22,96817,170 total
  • Sale

    Common Stock

    2025-12-03$30.34/sh789$23,93716,381 total
  • Sale

    Common Stock

    2025-12-03$30.85/sh1,225$37,78815,156 total
  • Exercise/Conversion

    Restricted Stock Units

    2025-12-0111,9810 total
    Exp: 2025-12-01Common Stock (11,981 underlying)
Footnotes (7)
  • [F1]The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.93 to $29.92 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5.
  • [F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.93 to $30.63 per share, inclusive.
  • [F4]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.81 to $30.805 per share, inclusive.
  • [F5]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.815 to $31.17 per share, inclusive.
  • [F6]Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
  • [F7]48,792 restricted stock units vested on December 1, 2024 and 11,981 vest on December 1, 2025, subject to the reporting person's continued service to the Issuer on each such date.

Issuer

Stoke Therapeutics, Inc.

CIK 0001623526

Entity typeother

Related Parties

1
  • filerCIK 0001780088

Filing Metadata

Form type
4
Filed
Dec 2, 7:00 PM ET
Accepted
Dec 3, 8:23 PM ET
Size
14.7 KB